Aug 25, 2010 · Patients who have been previously treated with flibanserin
Despite a need for additional study in diverse populations, flibanserin has demonstrated efficacy with increased female sexual function index (FSFI) total and
Flibanserin is the first drug in its class to treat FSIAD in premenopausal women
Data
1% of placebo Flibanserin is the
FSFI data pooled from 3 pivotal flibanserin trials in premenopausal women (flibanserin = 1,165; placebo = 1,203) and FSFI data from one complete flibanserin trial in
Testosterone, buspirone, sildenafil, bupropion, bremelanotide, as well as herbal medications (Herbal vX or Tribulus terrestris) have demonstrated some clinical
Importance: In August 2015, the US Food and Drug Administration (FDA) approved flibanserin as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, despite concern about suboptimal risk-benefit trade-offs
Clayton AH, Croft HA, Yuan J, et al
Developed by the pharmaceutical company Boehringer Ingelheim, flibanserin has been through many vigorous clinical trials
Flibanserin is the first and only FDA approved medication for the treatment of in women
1% of placebo Flibanserin is the first medicine of its kind to be approved for the treatment of FSIAD in premenopausal women
(Clinical Trial) Actual Enrollment : 748 participants Yuan J, Kissling R, Kingsberg SA
4
12
Debates about the condition aside, Boehringer Ingelheim, the company that originally developed flibanserin, and Sprout, which acquired the drug in 2012, tested the drug in clinical trials in which Introduction: Hypoactive sexual desire disorder (HSDD) is the most prevalent sexual dysfunction in women, previously managed with off-label therapies
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria
Three clinical trials testing flibanserin were consistent in their results
Standards for clinical trials in sexual dysfunction in women: in United States women revisted Hide glossary Glossary
It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder - Full Text View